Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy

Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra‐physiological doses of testosterone. Administration of supra‐physiological doses of testosterone might re‐sensitize cancer cells to various treatment modalities including hormonal and chemotherapy. It is a safe treatment option also for patients on hemodialysis.